Skip to main content

Pharma News

pharma courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • IIHMR University Bids Farewell to 334 Graduates at the Annual Convocation

    IIHMR University, a leading health management research university in India, on July 20 th successfully wrapped up its Annual Convocation, at the pristine campus in Jaipur, Rajasthan. The momentous occasion marked a milestone event in the lives of 334 students who were conferred with their well-deserved degrees.
  • Zydus announces non-exclusive patent licensing agreement with Takeda for Vault Vonoprazan in India
    Zydus Lifesciences Limited discovery-driven global lifesciences company has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker P-CAB Vonoprazan in India.
  • Diabetes Drug Reduces Drug Resistance in Lung Cancer
    A medication used to treat diabetic neuropathy may make chemotherapy treatments more effective for patients with lung cancer, according to new findings from the University of Missouri School of Medicine published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
  • New gene therapy for muscular dystrophy offers hope
    A new gene therapy treatment for Duchenne muscular dystrophy shows promise of not only arresting the decline of the muscles of those affected by this inherited genetic disease, but perhaps, in the future, repairing those muscles.
  • Supplements slow disease progression during late stage of dry age-related macular degeneration
    In a new analysis of data, researchers at the National Institutes of Health (NIH) have found that taking a daily supplement containing antioxidant vitamins and minerals slows progression of late-stage dry age-related macular degeneration (AMD), potentially helping people with late-stage disease preserve their central vision. Researchers reviewed the original retinal scans of participants in the Age-Related Eye Diseases Studies (AREDS and AREDS2) and found that
  • Harnessing big data helps scientists hone in on new antimicrobials
    Researchers have developed a strategy to identify new antimicrobial drugs with therapeutic promise from bacterial datasets, providing clues for discovering alternatives to traditional antibiotics.
  • Same workout, different weight loss: Signal molecule versions are key

    Some people lose weight slower than others after workouts, and a Kobe University research team found a reason. They studied what happens to mice that cannot produce signal molecules that respond specifically to short-term exercise and regulate the body’s energy metabolism. These mice consume less oxygen during workouts, burn less fat and are thus also more susceptible to gaining weight. Since the team found this connection also in humans, the newly gained knowledge of this mechanism might provide a pathway for treating obesity. 

  • Distinct T-cell signatures observed at different stages of type 1 diabetes development
    A study conducted at the University of Eastern Finland found distinct signatures in CD8-positive T cells in blood samples from children with newly diagnosed type 1 diabetes and in autoantibody-positive children who later developed type 1 diabetes. The study was published in the journal Diabetes.
  • Phage-Derived Enzyme Targets E. faecalis Biofilms to Mitigate Acute Graft-Versus-Host Disease

    Acute graft-versus-host disease (aGVHD) is a medical condition that occurs when donor immune cells attack the recipient's tissues after an allogeneic hematopoietic stem cell transplantation (allo-HCT). The pathogenesis of aGVHD is influenced by gut dysbiosis and Enterococcus domination. Researchers from Japan recently identified a bacteriophage-derived enzyme called endolysin capable of targeting biofilms formed by Enterococcus faecalis. Their findings offer hope for tailored interventions in allo-HCT.

  • Sleep timer for immune cells discovered
    In chronic hepatitis B, the liver contains immune cells that could destroy hepatitis B virus-infected cells but are inactive. A team from the Technical University of Munich has discovered that cells in blood vessels in the liver start a sleep timer that switches off immune cells. Targeting this mechanism could be a starting point for immunotherapies.
Subscribe to Pharma News